Cancer Research
According to the National Cancer Institute, in 2022,
about 600,000 people will die of cancer.
Cancer is a leading cause of death in the United States, and LC Sciences is dedicated to providing cancer researchers and clinicians the tools and services they need to continue to fight this devastating disease that affects so many of us.
Personalized cancer treatment is being made possible by advanced diagnostic and informatics approaches that provide understanding of the molecular basis of disease.
![breast-cancer Breast Cancer](jpg/breast-cancer-1.jpg)
Breast cancer is one of the most common types of cancer and has the highest cancer-specific mortality rate in women worldwide. It is therefore essential to better understand the underlying molecular mechanisms and to develop novel approaches for the prevention, treatment, and management of breast cancer. Currently, treatment strategy for breast cancer include locoregional treatment with surgery and radiation, plus systemic treatment with chemotherapy, endocrine, and biologic therapies1.
Chemotherapy has been well established as a mainstay for the treatment of breast cancer, improving the prognosis and survival rate of patients with breast cancer. Despite their efficacy, there is still a subset of patients who do not respond to chemotherapeutic drugs and, as a result, have a much poorer prognosis. Molecular mechanisms of chemotherapy resistance have been correlated with both genetic and epigenetic changes, including drug-induced mutations, aberrations of drug metabolic enzymes, cell cycle- and apoptosis-associated genes, DNA methylation and histone modifications2.
LC Sciences is helping clinicians and researchers with:
![lung-cancer Lung Cancer](jpg/lung-cancer.jpg)
Accounting for 1.2 million deaths each year, non-small cell lung cancer (NSCLC) is the primary cause of cancer mortality in both sexes, with an overall five-year survival rate of only 10–15%. Despite therapeutic advances in recent years, the high mortality of patients with NSCLC has not been substantially reduced, largely because of the potential of invasion, metastasis, and frequent recurrence. Thus there is an urgent need for developing therapeutic methods to improve the outcome of patients with lung cancer. In NSCLC, the leading death cause is chemotherapy resistance and metastasis, yet the underlying mechanisms of them remain largely unclear1.
Therapeutic responses to drugs such as gefitinib may persist for as long as 2–3 years; however, drug resistance eventually emerges and this limits the mean duration of response to 6–8 months. Recent advances in bioinformatics and high-throughput technologies, such as microarray analysis, are increasing the understanding of the molecular mechanisms underlying drug sensitivity and biological processes2.
LC Sciences is helping clinicians and researchers with:
![prostate-cancer Prostate Cancer](jpg/prostate-cancer-2.jpg)
Prostate cancer (PCa) has become one of the most common malignancies in men worldwide, with strongly varying rates of tumor progression and responses to treatment. If the tumor is confined to the prostate, patients can be treated by surgical removal of the tumor or by radiation, with high efficacy. By contrast, therapy for unconfined tumors still represents a major problem1.
Though cancer metastasis is a highly complex multi-step process facilitated by several key events and molecular players, the most effective way known to prevent this progression is by identifying and targeting the various genes involved in the process(es)2.
A number of techniques are currently available for assessing prostate health, the most common of which include digital rectal exam (DRE), trans-rectal ultrasonography (TRUS), and prostate specific antigen-based testing (PSA), however, miRNA expression “signatures” are expected to offer serious potential for diagnosing and prognosing cancers in the near future3.
LC Sciences is helping clinicians and researchers with:
![pancreatic-cancer Pancreatic Cancer](jpg/pancreatic-cancer.jpg)
Pancreatic cancer exhibits aggressive features with 1-year relative survival rate of only 21% . Such high mortality of pancreatic cancer could in part be due to the capacity of pancreatic cancer cells to acquire rapid cell proliferative, invasive, and metastatic characteristics during the development and progression of pancreatic cancer. Only early pancreatic cancers can be removed by surgery. Unfortunately, early pancreatic cancer only accounts for a very small numbers of patients (about 20% of all pancreatic cancer diagnosed). Moreover, chemotherapies for unresectable pancreatic cancer are not effective for most patients. Therefore, it is important to understand the molecular mechanism(s) involved in the aggressive growth characteristics of pancreatic cancer. By knowing the altered molecular signaling in pancreatic cancer, novel targeted and combination therapies could be designed to inhibit the aggressiveness of pancreatic cancer so that the patients with pancreatic cancers could be treated with better outcome1.
LC Sciences is helping clinicians and researchers with:
Cancer Research Services
LC Sciences offers a range of services applicable to
clinical cancer research. Contact us to find out more.